Ticker
YMABCompany Name
Y-MABS THERAPEUTICS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQDate | Debt to Equity Ratio | Shareholders Equity | Total Liabilities |
---|---|---|---|
6/30/2025 | 0.34 | $ 87.49M | $ 29.72M |
3/31/2025 | 0.26 | $ 89.46M | $ 23.16M |
12/31/2024 | 0.3 | $ 92M | $ 27.9M |
9/30/2024 | 0.31 | $ 92.43M | $ 28.49M |
6/30/2024 | 0.51 | $ 95.34M | $ 48.7M |
3/31/2024 | 0.24 | $ 99.19M | $ 24.13M |
12/31/2023 | 0.27 | $ 100.98M | $ 26.88M |
9/30/2023 | 0.29 | $ 100.15M | $ 28.73M |
6/30/2023 | 0.26 | $ 104.68M | $ 27.71M |
3/31/2023 | 0.27 | $ 107.83M | $ 29.62M |
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
Liabilities / Equity
(=) D/E
D/E for Y-MABS THERAPEUTICS INC is calculated as follows: Liabilities [ $ 26.68M ] / Equity [ $ 116.51M ]
(=) D/E [ 0.23 ]
Minimum
Mar 31, 2021
Maximum
Jun 30, 2024
Average
Median
filtered constituents | 3.3K |
---|---|
min | 0 |
max | 6.03 |
average | 1.39 |
median | 0.98 |
std | 1.31 |